Synthesis and neuroprotective activity of 3-aryl-3-azetidinyl acetic acid methyl ester derivatives

Arch Pharm (Weinheim). 2023 Dec;356(12):e2300378. doi: 10.1002/ardp.202300378. Epub 2023 Oct 5.

Abstract

A library of 3-aryl-3-azetidinyl acetic acid methyl ester derivatives was prepared from N-Boc-3-azetidinone employing the Horner-Wadsworth-Emmons reaction, rhodium(I)-catalyzed conjugate addition of arylboronic acids, and subsequent elaborations to obtain N-unprotected hydrochlorides, N-alkylated and N-acylated azetidine derivatives. The compounds were evaluated for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activity, revealing several derivatives to possess AChE inhibition comparable to that of the AChE inhibitor rivastigmine. The binding mode of the AChE inhibitor donepezil and selected active compounds 26 and 27 within the active site of AChE was studied using molecular docking. Furthermore, the neuroprotective activity of the prepared compounds was evaluated in models associated with Parkinson's disease (salsolinol-induced) and aspects of Alzheimer's disease (glutamate-induced oxidative damage). Compound 28 showed the highest neuroprotective effect in both salsolinol- and glutamate-induced neurodegeneration models, and its protective effect in the glutamate model was revealed to be driven by a reduction in oxidative stress and caspase-3/7 activity.

Keywords: Alzheimer disease; Parkinson disease; acetylcholinesterase; azetidine; neuroprotection.

MeSH terms

  • Acetylcholinesterase / metabolism
  • Alzheimer Disease* / drug therapy
  • Butyrylcholinesterase / metabolism
  • Cholinesterase Inhibitors / chemistry
  • Glutamates / therapeutic use
  • Humans
  • Molecular Docking Simulation
  • Neuroprotective Agents* / chemistry
  • Neuroprotective Agents* / pharmacology
  • Structure-Activity Relationship

Substances

  • Butyrylcholinesterase
  • Acetylcholinesterase
  • methyl acetate
  • Cholinesterase Inhibitors
  • Neuroprotective Agents
  • Glutamates